88071-90-3

Basic information

• Product Name: Benzoic acid, 3-(bromomethyl)-4-nitro-, methyl ester
• CAS NO: 88071-90-3
• Molecular Formula: C9H8BrNO4
• Molecular Weight: 274.071
• Mol File: 88071-90-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-(bromomethyl)-4-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-(bromomethyl)-4-nitro-, methyl ester(88071-90-3)
• EPA Substance Registry System: Benzoic acid, 3-(bromomethyl)-4-nitro-, methyl ester(88071-90-3)

Safety Data

• Hazardous Substances Data: 88071-90-3(Hazardous Substances Data)

Upstream product

• 201932-92-5 methyl 3-(hydroxymethyl)-4-nitrobenzoate 
• 148625-35-8 methyl 3-formyl-4-nitrobenzoate 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 24078-21-5 methyl 3-methyl-4-nitrobenzoate 

Downstream Products

• 88071-94-7 nitro-4 phenoxymethyl-3 benzoate de methyle 

Relevant articles and documents

N-transfer reagent and method for preparing the same and its application

Provided are a novel N-transfer reagent and a method for preparing the same and its application. The N-transfer reagent is represented by the following Formula (I): The various novel N-transfer reagents of the present invention can be quickly prepared by employing different nitrobenzene precursors. The N-transfer reagents can directly convert a variety of amino compounds into diazo compounds under mild conditions. Particularly, the N-transfer reagents can facilitate the synthesis of the diazo compounds. The application of synthesizing diazo compounds of the present invention can greatly decrease the difficulty in operation, increase the safety during experiments, reduce the cost of production and the environmental pollution, and enhance the industrial value of diazo compounds.

Synthesis of a benzene-containing C1-phosphonate analogue of UDP-GlcNAc for the inhibition of O-GlcNAc transferase

I report here the design, synthesis, and biological evaluation of a new C1-phosphonate analogue of UDP-GlcNAc as a potential inhibitor of OGT, an enzyme responsible for O-GlcNAc modification. The analogue was designed to mimic the transition state of the

NEOSEPTINS: SMALL MOLECULE ADJUVANTS

A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.